ENHERTU® Wins FDA First‑Line Approval, Boosts Daiichi Sankyo’s Breast Cancer Strategy
Discover how Daiichi Sankyo’s FDA‑approved ENHERTU® with pertuzumab and AI‑driven biomarker work reshape HER2‑positive breast cancer treatment, boosting clinical and market prospects.
3 minutes to read
